Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...

with intravenous as well as subcutaneous formulations. HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma.

Dr. Reddy’s (NYSE:RDY) on Thursday announced a licensing agreement with China-based Shanghai Henlius Biotech (OTCPK:SGBCF) to jointly develop and market a biosimilar version of Darzalex, a multiple ...

Analysts think the shorter treatment of Darzalex Faspro time could become a particularly important advantage over the established formulation during the coronavirus pandemic, when getting access ...

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

The darzalex faspro market witnessed significant growth in recent years with recorded XX in historic compound annual growth rate HCAGR. Within a year, the market size ...

What Does the Darzalex Faspro Market Look Like? The darzalex faspro market witnessed significant growth in recent years with recorded XX in historic compound annual growth rate HCAGR. Within a ...

Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...

Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...

New Delhi: Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius ...